Literature DB >> 11913996

Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura.

R McMillan1.   

Abstract

Treatment of chronic immune (idiopathic) thrombocytopenic purpura with corticosteroids and/or splenectomy results in safe platelet counts in over 70% of patients without additional treatment. Therapy of patients who are refractory to these two treatments may be difficult. The treatment approach to refractory ITP patients, described in this report, is arbitrarily divided into four levels: levels 1 through 3 represent treatments with increasing side effects; level 4 therapy may be tried when the others have failed. Patients undergoing these treatments may require concomitant intravenous gammaglobulin, high-dose corticosteroids or platelets, to maintain the platelet count in the setting of mucosal bleeding or severe thrombocytopenia. Copyright 2002, Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11913996     DOI: 10.1054/blre.2001.0183

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  3 in total

Review 1.  Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol.

Authors:  Emmanuel Andrès; Jacques Zimmer; Esther Noel; Georges Kaltenbach; Argyro Koumarianou; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

2.  Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.

Authors:  Jaime Garcia-Chavez; Abraham Majluf-Cruz; Laura Montiel-Cervantes; Miriam García-Ruiz Esparza; Jorge Vela-Ojeda
Journal:  Ann Hematol       Date:  2007-09-14       Impact factor: 3.673

3.  Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.

Authors:  Füsun Özdemirkıran; Bahriye Payzın; H Demet Kiper; Sibel Kabukçu; Gülsüm Akgün Çağlıyan; Selda Kahraman; Ömür Gökmen Sevindik; Cengiz Ceylan; Gürhan Kadıköylü; Fahri Şahin; Ali Keskin; Öykü Arslan; Mehmet Ali Özcan; Gülnur Kabukçu; Gülsüm Görgün; Zahit Bolaman; Filiz Büyükkeçeci; Oktay Bilgir; İnci Alacacıoğlu; Filiz Vural; Murat Tombuloğlu; Zafer Gökgöz; Güray Saydam
Journal:  Turk J Haematol       Date:  2015-04-27       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.